Combinations of either brodimoprim or trimethoprim plus either carbenicillin, gentamicin, ciprofloxacin or rifampicin showed synergy at sub-inhibitory concentrations against both Enterococcus faecalis NCTC 5957 and 775. Brodimoprim alone and in combination showed greater antibacterial activity against both strains of E. faecalis than trimethoprim. MBCs of brodimoprim and trimethoprim were 14.4 and 25.6 mg/L for E. faecalis NCTC 5957 and 7.2 and 12.8 mg/L for E. faecalis NCTC 775. Combinations of either brodimoprim or trimethoprim plus the other antibacterial agents, except gentamicin and dibromopropamidine isethionate, were bactericidal at achievable plasma concentrations. Viable count determinations of cultures of both test organisms in the presence of 3/4 of the MIC of each of the four antibiotics and the two antifolates alone and combinations of each antibiotic with either brodimoprim or trimethoprim indicated that only the combinations prevented recovery and regrowth of the cultures over 24 h. The ATP released from cultures of both strains of E. faecalis treated with brodimoprim and tnmethoprim at the same concentrations was approximately 1.5 times greater with brodimoprim than with trimethoprim. Combinations of 3/4 of the MIC of each of the antibiotics in combination with 3/4 of the MIC of brodimoprim against cultures of both strains of E. faecalis resulted in greater release of ATP than occurred with equivalent trimethoprim combinations. It is postulated that the increased activities observed with the brodimoprim combinations resulted from an effect of brodimoprim on the bacterial cell permeability control. These results indicate that both brodimoprim and trimethoprim offer potential benefits for use with either carbenicillin, gentamicin, ciprofloxacin or rifampicin for the treatment of E. faecalis infections.
Introduction
Trimethoprim exhibits antibacterial activity against Enterococcus faecalis even though E. faecalis has the ability to utilize partially exogenous folates (Bushby & Hitchings, 1968; Hamilton-Miller & Purves, 1986; Hamilton-Miller, 1988; Zervos & Szhaberg, 1985) . Synergy was obtained with combinations of trimethoprim plus sulphonamide against 126 strains of E. faecalis (Crider & Colby, 1985) and even with strains resistant to trimethoprim (Hamilton-Miller & Stewart, 1988) .
Brodimoprim is a selective inhibitor of bacterial dihydrofolate reductase and has a broad spectrum of activity similar to that observed for trimethoprim (Amyes, 1993) but it has a half-life which is four-times greater than trimethoprim (Weidekamm, 1993) . Brodimoprim is reported to be more effective than trimethoprim against Gram-positive bacteria (Amyes, 1993) and this may be because brodimoprim is able to penetrate Gram-positive bacterial cells more readily because of the presence of the bromine atom in the molecule (Bohni & Then, 1982; Bowden, Harris & Watson, 1993) . Brodimoprim was shown to be active against E. faecalis (Amyes, 1993; Benoit-Lemercier, Bergogne-Berezin & Joly-Guillou, 1993; Nicoletti, Novelli & Periti, 1993) . However, when used alone, both brodimoprim and trimethoprim were only bacteriostatic at levels obtainable in plasma (Benoit-Lemercier et al., 1993) .
Some benefit was obtained when trimethoprim plus carbenicillin was used for treatment of infections in immunodeficient patients (Young & Hindler, 1987) and when trimethoprim plus rifampicin was used in urinary tract infection caused by E. faecalis (Brumfitt & Hamilton-Miller, 1982) . Combinations of trimethoprim plus ciprofloxacin against E. faecalis have also been evaluated in vitro (Huovinen, Wolfson & Hooper, 1992) . Enhancement of activity produced by trimethoprim with other antibacterials against E. faecalis was shown to be related to increased bacterial uptake of the antibacterials (Richards, Taylor & Xing, 1993; Richards et al., 1995) resulting from trimethoprim damage to the cell envelope (Richards et al., 1995) .
The present study was undertaken to investigate the mechanism of action and activity of brodimoprim alone and in combination against E. faecalis compared with the activity of trimethoprim combinations in order to assess the potential clinical role for such combinations.
Materials and methods
E. faecalis NCTC 775 and 5957 were obtained from the National Collection of Type Cultures, Public Health Laboratory Service, Colindale Avenue, London. Nutrient broth, Iso-sensitest broth and nutrient agar (Oxoid, Basingstoke) containing 0.25% glucose were the culture media.
Brodimoprim was a gift from Helsinn Healthcare SA (Chiasso, Switzerland) and dibromopropamidine isethionate (DBPI) was a gift from Rhone Poulenc, Rorer (UK). Trimethoprim, carbenicillin, gentamicin, ciprofloxacin and rifampicin were all obtained from Sigma (Poole, UK).
Minimum inhibitory concentrations (MICs)
A microdilution method was employed for the MIC determinations. Antibacterial solutions were freshly prepared each day and serial doubling dilutions prepared in Iso-sensitest broth containing 0.25% glucose to produce final concentrations ranging from 0.125 to 512 mg/L, as appropriate for the antibacterial being tested, to obtain the approximate MICs. Accurate MICs were determined from the approximate MICs by using a series of 10% stepwise reductions in concentration. Duplicate antibacterial solutions were distributed in volumes of 100 ^L per microtitre tray well and inoculated with 100 nL of bacterial suspension from an 18 h culture to give a final concentration of 5 x 10 3 cfu/mL (this was confirmed by viable counts). After 24 h incubation at 37°C the lowest concentration of each antibacterial which inhibited growth in duplicate wells was taken to be the MIC.
Minimum bactericidal concentrations (MBCs)
MBCs were determined by plating 10 /iL from the clear wells of the microtitre trays used for determining approximate MICs to overdried nutrient agar plates. After incubation for 24 h at 37°C the approximate MBCs were taken to be the lowest antibacterial concentrations that killed 99.9% of the original inoculum. Accurate MBCs were determined from the approximate MBCs by using a series of 10% stepwise reductions in concentration.
Determination of antibacterial activities in combination
The microtitre checkerboard technique was used to determine the MICs for antibacterial combinations (Huovinen et al., 1992) . The two antibacterials 'X' and 'Y' to be tested in combination were prepared separately in Iso-sensitest broth containing 0.25% glucose to give concentrations four times greater than the accurate MICs. These were diluted by 10% gradations and in two series. Fifty microlitre volumes of each of the dilutions of antibacterial 'X' were dispensed into the appropriate column of microtitre tray wells. Then 50 fiL of each of the dilutions of antibacterial 'Y' were added to the appropriate row of the tray wells. An inoculum of 100 /iL of bacterial suspension was added to each of the wells to give a final concentration of lO'cfu/mL. The concentration of each paired concentration of 'X' and 'Y' in each well was then 1/4 of the concentration originally placed in the well. The tray was then covered with cling film and incubated at 37°C for 24 h. The fractional inhibitory concentration indices (FIC indices) were calculated as described ). An FIC index of 0.7 was taken to represent synergy and an FIC index of greater than 0.7, but less than 1.3 was taken to represent addition. An FIC index ^1.3 was taken to represent antagonism (Richards, Taylor & Xing, 1991) .
Determination of bacterial viability
The microdilution viable counting method was employed for both E. faecalis NCTC 775 and NCTC 5957. Three quarters of the MIC value for each antibacterial agent was tested singly and in combination to ensure that the concentration used was subinhibitory. An inoculum of 1 mL of an 18 h culture was added to separate flasks containing 99 mL of Iso-sensitest broth with or without the appropriate antibacterial agents to give a final concentration of approximately 5 x 10 5 cfu/mL. At intervals of 30 min, 1, 2, 3, 4, 5 and 24 h 10 /iL of each culture was serially diluted in nutrient broth. Samples of 10 //L from each dilution were plated in triplicate on overdried nutrient agar plates and incubated at 37°C for 24 h before counting.
Assessment of bacterial permeability
The measurement of extracellular ATP was used to evaluate the leakage from both test organisms grown separately in the presence of selected concentrations of either brodimoprim or trimethoprim. Leakage of ATP was also determined to assess damage to bacterial permeability caused by growing the test organisms in 3/4 of the MIC of each antibacterial agent alone (except DBPI) and of each antibiotic in combination with either brodimoprim or trimethoprim. The bioluminescence ATP assay was described by Richards et al. (1995) .
Results
The MIC, FIC indices and MBC of brodimoprim and trimethoprim either alone or in paired combinations with carbenicillin, gentamicin, ciprofloxacin, DBPI and rifampicin for NCTC 5957 and NCTC 775 are presented in Tables I and II respectively. For the combination of brodimoprim plus DBPI, the FIC indices were 1.5 for E. faecalis NCTC 5957 and 1.6 for E. faecalis NCTC 775 which showed antagonism for this combination. Combinations of brodimoprim or trimethoprim plus either carbenicillin, gentamicin, ciprofloxacin or rifampicin at sub-inhibitory concentrations all showed synergy against both test organisms (Tables I and II ). The combination of trimethoprim and carbenicillin against E. faecalis NCTC 5957 was never the less seen to be borderline.
MBCs of brodimoprim, trimethoprim, carbenicillin, gentamicin, ciprofloxacin and rifampicin alone against both test organisms were all near to or higher than the concentrations of each antibacterial agent reported to be obtainable in plasma (Burman, 1986; Reynolds, 1993; Stockis et al., 1993; Weidekamm, 1993) .
Figures 1 and 2 indicate the effects of three quarters of the MIC of each antibacterial agent alone and in combination with either brodimoprim or trimethoprim against E. faecalis NCTC 5957 and NCTC 775 respectively. For E. faecalis NCTC 5957 (Figure 1) , both brodimoprim 0.34 mg/L and trimethoprim 0.53 mg/L maintained an inhibitory effect over 5 h, but after 24 h the cultures had recovered to counts of approximately 1.5 x 10 6 cfu/mL treated by brodimoprim and 1.2 x 10 7 cfu/mL treated by trimethoprim. Carbenicillin 48 mg/L used singly only caused a reduction in growth rate but the combination of either brodimoprim 0.34 mg/L or trimethoprim 0.53 mg/L plus carbenicillin 43.2 mg/L produced a reduction in cfu over the whole 24 h. Gentamicin 33.6 mg/L had an inhibitory effect for about 3 h and then started to recover but the combination of either brodimoprim 0.34 mg/L or trimethoprim 0.53 mg/L plus gentamicin 33.6 mg/L reduced the count to approximately 2.6 x lO-'cfu/mL within 3-5 h. Both ciprofloxacin 1.35 mg/L and rifampicin 1.35 mg/L used singly caused an inhibition in growth rate for 4-5 h but the combination of brodimoprim 0.34 mg/L plus ciprofloxacin 1.35 mg/L reduced the count to approximately 3.8 x 10 3 cfu/mL within 5 h and trimethoprim 0.53 mg/L plus ciprofloxacin 1.35 mg/L produced a reduction in cfu over the whole 24 h. Either brodimoprim 0.34 mg/L or trimethoprim 0.53 mg/L plus rifampicin 1.35 mg/L not only reduced the count over the first 2 h for the trimethoprim combination and over 5 h for brodimoprim combination but maintained this reduction over 24 h. Figure 2 shows that similar effects were observed when the same antibacterial agents were used again at three quarters of the MIC singly or in combination against E. faecalis NCTC 775. Brodimoprim 0.45 or 0.225 mg/L (equivalent to the MICs) produced respective ATP leakages of 0.89 pmol for E. faecalis NCTC 5957 (Figure 3(a) ) and 0.93 for E. faecalis NCTC 775 (Figure 3(b) ) compared with leakages of 0.73 and 0.77 pmol induced by trimethoprim 0.45 and 0.225 mg/L respectively. The ATP leakages resulting from the growth of the two strains of E. faecalis in the presence three quarters of the MIC of each antibacterial agent alone and in combination with brodimoprim or trimethoprim are given in Figure 4 . The ATP released from E. faecalis NCTC 5957 cells grown in the presence of brodimoprim was 0.87 pmol (Figure 4(a) ). This was approximately three times greater than for the control and also greater than the 0.73 pmol released following growth in the presence of trimethoprim. For single antibacterial agents the leakages caused by brodimoprim or trimethoprim alone were only exceeded by carbenicillin. For the combinations, the ATP concentrations released by E. faecalis NCTC 5957 were 1.35 pmol for brodimoprim plus carbenicillin, 1.18 for brodimoprim plus gentamicin, 1.14 for brodimoprim plus ciprofloxacin and 1.15 for brodimoprim plus rifampicin. Similar results were obtained with E. faecalis NCTC 775 (Figure 4{b) ). The release of ATP produced by the trimethoprim combinations with both strains of E. faecalis was always greater than the release produced by the single antibacterials, but was always less than that produced by the brodimoprim combinations.
Discussion
Brodimoprim was more active than trimethoprim against both strains of E. faecalis. For E. faecalis NCTC 775 and NCTC 5957 the MICs of brodimoprim were 0.225 and 0.45 mg/L respectively compared with 0.35 and 0.7 mg/L for trimethoprim. The MBCs of brodimoprim and trimethoprim alone for both strains were higher than achievable plasma concentration levels (Tables I and II) . The MBC/MIC ratios were 32 for brodimoprim and 36.5 for trimethoprim and these ratios are similar to published data (Benoit-Lemercier et al., 1993) mean MBC/MIC ratios of 25 for trimethopnm and 37 for brodimoprim. These high MBC/MIC ratios indicate that both trimethopnm and brodimoprim alone would only have a bacteriostatic effect against E.faecalis in vivo.
The E. faecalis strains tested in this investigation were sensitive to carbenicillin, ciprofloxacin and rifampicin. However, MBCs of carbenicillin, gentamicin, ciprofloxacin and rifampicin alone for these strains were either close to, or higher than the achievable plasma concentrations.
The synergy between sub-inhibitory concentrations of brodimoprim plus any of the other antibacterial agents tested except DBPI, as determined by the FICs, was supported by the prolonged effect of the brodimoprim combinations on growth rates. The combination of brodimoprim plus DBPI resulted in antagonism for both strains. This was different from the synergy obtained with a combination of trimethoprim plus DBPI. This antagonism is very likely the result of the antibacterial activity of both molecules being associated with the cation. The two cations would then compete for negatively-charged sites on the bacterial surface and the consequence would be antagonism of antibacterial activity.
FIC indices indicated that either brodimoprim alone or in combination with other antibacterial agents was usually more active against both strains of E. faecalis than trimethoprim alone or in combination (Tables I and II) .
Figures 3 and 4 show that brodimoprim increased ATP leakage from the test organisms and implies that brodimoprim affects bacterial cell permeability control as has been reported for trimethoprim (Richards et al., 1993a (Richards et al., , 1995 and penicillin (Winstanley & Hastings, 1989 , 1990 . This provides an explanation of how brodimoprim is effective in enhancing the activity of other antibacterials by increasing their uptake by the damaged bacterial cells in a similar way to that reported for sulphonamides and trimethoprim Richards et al., , I993a,b, 1995 . Figures 3 and 4 indicate that the greater activities of brodimoprim combinations compared with trimethoprim combinations are related to the greater effect of brodimoprim on the permeability control of E. faecalis cells.
The results presented here show that both brodimoprim and trimethoprim when used in combination with either carbenicillin, gentamicin, ciprofloxacin or rifampicin have the potential to be effective clinically against E. faecalis infections. 
